EDITAS MEDICINE, INC. (EDIT) Current Ratio
- Current ratio · latest quarter: Value 3.19×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.19× | Current assets / current liabilities. $218.07M ÷ $68.43M ≈ 3.19× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 218.07M USD | Assets, Current |
| Current obligations | 68.43M USD | Liabilities, Current |
| Cash and equivalents | 181.81M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 29.83M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.74M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 7.50M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $218.07M | $68.43M | $181.81M | $29.83M | (m) | (m) | $4.74M | $7.50M | 3.19× |
| 2026-03-31 | $128.07M | $39.78M | $123.65M | (m) | (m) | (m) | $4.33M | $7.50M | 3.22× |
| 2025-12-31 | $163.90M | $46.25M | $146.65M | $0.00 | (m) | (m) | $2.60M | $5.00M | 3.54× |
| 2025-09-30 | $176.89M | $61.77M | $165.65M | $0.00 | (m) | (m) | $3.16M | $5.00M | 2.86× |
| 2025-06-30 | $182.80M | $65.94M | $138.54M | $39.96M | (m) | (m) | $6.72M | $5.00M | 2.77× |
| 2025-03-31 | $224.84M | $73.11M | $138.69M | $82.27M | (m) | (m) | $5.46M | $5.00M | 3.08× |
| 2024-12-31 | $289.31M | $77.22M | $131.54M | $138.37M | (m) | (m) | $5.49M | $5.00M | 3.75× |
| 2024-09-30 | $271.14M | $72.35M | $95.83M | $169.26M | (m) | (m) | $12.49M | (m) | 3.75× |
| 2024-06-30 | $286.35M | $74.31M | $64.44M | $214.67M | (m) | (m) | $13.77M | (m) | 3.85× |
| 2024-03-31 | $305.56M | $66.49M | $69.23M | $226.94M | (m) | (m) | $7.97M | (m) | 4.60× |
| 2023-12-31 | $340.83M | $63.22M | $123.65M | $199.46M | (m) | (m) | $8.27M | $0.00 | 5.39× |
| 2023-09-30 | $358.60M | $58.60M | $82.54M | $267.08M | (m) | (m) | $10.41M | (m) | 6.12× |
| 2023-06-30 | $440.98M | $54.51M | $220.82M | $211.15M | (m) | (m) | $8.07M | (m) | 8.09× |
| 2023-03-31 | $324.46M | $57.16M | $129.02M | $189.42M | (m) | (m) | $9.05M | (m) | 5.68× |
| 2022-12-31 | $356.75M | $60.11M | $141.52M | $202.75M | (m) | (m) | $9.51M | (m) | 5.94× |
| 2022-09-30 | $426.63M | $42.29M | $210.70M | $208.91M | (m) | (m) | $6.84M | (m) | 10.09× |
| 2022-06-30 | $461.38M | $36.42M | $169.40M | $283.16M | (m) | (m) | $6.17M | (m) | 12.67× |
| 2022-03-31 | $497.03M | $36.50M | $210.88M | $277.48M | (m) | (m) | $4.69M | (m) | 13.62× |
| 2021-12-31 | $507.31M | $46.88M | $203.52M | $296.33M | (m) | (m) | $5.05M | (m) | 10.82× |
| 2021-09-30 | $567.61M | $50.91M | $259.88M | $297.96M | (m) | (m) | $3.40M | (m) | 11.15× |
| 2021-06-30 | $616.29M | $66.02M | $337.83M | $272.72M | (m) | (m) | $4.42M | (m) | 9.34× |
| 2021-03-31 | $632.32M | $64.01M | $354.92M | $270.42M | (m) | (m) | $8.91M | (m) | 9.88× |
| 2020-12-31 | $419.09M | $58.21M | $139.68M | $262.43M | (m) | (m) | $6.41M | (m) | 7.20× |
| 2020-09-30 | $506.83M | $54.82M | $279.58M | $215.73M | (m) | (m) | $5.16M | (m) | 9.25× |
| 2020-06-30 | $610.13M | $68.15M | $485.82M | $112.90M | (m) | (m) | $6.34M | (m) | 8.95× |
| 2020-03-31 | $425.11M | $68.87M | $232.85M | $182.14M | (m) | (m) | $10.39M | (m) | 6.17× |
| 2019-12-31 | $463.84M | $59.96M | $238.18M | $218.96M | (m) | (m) | $5.84M | (m) | 7.74× |
| 2019-09-30 | $339.21M | $66.79M | $104.77M | $227.84M | (m) | (m) | $6.62M | (m) | 5.08× |
| 2019-06-30 | $324.24M | $72.87M | $210.60M | $107.33M | (m) | (m) | $3.98M | (m) | 4.45× |
| 2019-03-31 | $347.07M | $41.03M | $157.93M | $184.13M | (m) | (m) | $6.56M | (m) | 8.46× |
| 2018-12-31 | $374.78M | $35.90M | $134.78M | $234.18M | (m) | (m) | $5.33M | (m) | 10.44× |
| 2018-09-30 | $342.55M | $26.09M | $111.70M | $225.79M | (m) | (m) | $5.04M | (m) | 13.13× |
| 2018-06-30 | $348.24M | $24.02M | $131.92M | $212.16M | (m) | (m) | $4.66M | (m) | 14.50× |
| 2018-03-31 | $362.81M | $30.99M | $217.67M | $141.15M | (m) | (m) | $9.00M | (m) | 11.71× |
| 2017-12-31 | $332.20M | $36.71M | $146.63M | $182.51M | (m) | (m) | $4.02M | (m) | 9.05× |
| 2017-09-30 | $298.42M | $29.50M | $86.54M | $209.15M | (m) | (m) | $6.98M | (m) | 10.12× |
| 2017-06-30 | $327.87M | $48.69M | $144.10M | $180.70M | (m) | (m) | $8.16M | (m) | 6.73× |
| 2017-03-31 | $353.79M | $50.29M | $351.55M | (m) | (m) | (m) | $15.23M | (m) | 7.04× |
| 2016-12-31 | $187.18M | $33.08M | $185.32M | (m) | (m) | (m) | $4.64M | (m) | 5.66× |
| 2016-09-30 | $203.45M | $13.76M | $199.87M | (m) | (m) | (m) | $3.72M | (m) | 14.79× |
| 2016-06-30 | $221.22M | $13.72M | $217.65M | (m) | (m) | (m) | $5.84M | (m) | 16.12× |
| 2016-03-31 | $232.19M | $10.22M | $229.20M | (m) | (m) | (m) | $2.91M | (m) | 22.71× |
| 2015-12-31 | $144.99M | $6.92M | $143.18M | (m) | (m) | (m) | $1.38M | (m) | 20.94× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |